OverviewSuggest Edit

Merck is a healthcare manufacturer and distributor of pharmaceuticals. The Company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

TypePublic
Founded1891
HQKenilworth, US
Websitemerck.com
Employee Ratings3.9
Culture scoreB+

Latest Updates

Employees (est.) (Dec 2019)71,000(+3%)
Job Openings2,040
Revenue (FY, 2019)$46.8 B(+11%)
Share Price (May 2020)$77.3 (+2%)

Key People/Management at Merck

Kenneth Frazier

Kenneth Frazier

Chairman of the Board, CEO
Jim Scholefield

Jim Scholefield

Chief Information and Digital Officer
Robert Davis

Robert Davis

EVP, CFO
Mirian Graddick-Weir

Mirian Graddick-Weir

EVP
Julie Gerberding

Julie Gerberding

EVP
Sanat Chattopadhyay

Sanat Chattopadhyay

President, EVP
Show more

Merck Office Locations

Merck has offices in Kenilworth, Albany, Albuquerque, Alexandria and in 273 other locations
Kenilworth, US (HQ)
2000 Galloping Hill Rd
Albany, US
Albany, NY, USA
Albuquerque, US
Albuquerque, NM, USA
Alexandria, US
Alexandria, VA, USA
Allen, US
Allen, TX, USA
Allentown, US
Allentown, PA, USA
Show all (278)

Merck Financials and Metrics

Merck Revenue

Embed Graph
View revenue for all periods
Merck's revenue was reported to be $46.84 b in FY, 2019 which is a 10.7% increase from the previous period.
USD

Revenue (Q1, 2020)

12.1b

Gross profit (Q1, 2020)

8.7b

Gross profit margin (Q1, 2020), %

72.5%

Net income (Q1, 2020)

3.2b

Market capitalization (26-May-2020)

195.0b

Closing stock price (26-May-2020)

77.3

Cash (31-Mar-2020)

7.4b

EV

215.6b
Merck's current market capitalization is $195 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

40.1b42.3b46.8b

Revenue growth, %

1%5%11%

Cost of goods sold

12.8b13.5b14.1b

Gross profit

27.3b28.8b32.7b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

9.4b9.9b10.3b10.0b10.5b10.8b10.8b11.8b12.4b12.1b

Cost of goods sold

3.0b3.1b3.3b3.2b3.4b3.6b3.1b3.4b4.0b3.3b

Gross profit

6.4b6.9b7.1b6.9b7.0b7.2b7.8b8.4b8.4b8.7b

Gross profit Margin, %

68%69%68%68%67%66%72%71%68%73%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

6.1b8.0b9.7b

Accounts Receivable

6.9b7.1b6.8b

Inventories

5.1b5.4b6.0b

Current Assets

24.8b25.9b27.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

11.7b7.8b7.9b4.5b5.3b7.8b8.1b6.7b7.9b7.4b

Accounts Receivable

7.1b7.4b7.7b7.2b7.3b7.4b7.6b8.0b8.4b8.2b

Inventories

5.1b5.4b5.3b5.4b5.2b5.4b5.7b5.8b5.9b5.8b

Current Assets

31.5b28.2b27.9b24.1b24.1b26.8b25.4b24.3b26.1b26.2b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.4b6.2b9.8b

Depreciation and Amortization

4.6b4.5b3.7b

Inventories

(145.0m)(911.0m)(508.0m)

Accounts Payable

254.0m230.0m399.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

1.6b3.5b3.5b741.0m2.5b4.4b2.9b5.5b7.4b3.2b

Depreciation and Amortization

1.2b2.4b3.5b1.1b2.4b3.4b898.0m1.9b2.7b821.0m

Cash From Operating Activities

286.0m3.6b2.4b1.2b4.5b7.3b1.3b4.4b8.6b707.0m

Purchases of PP&E

(595.0m)(1.4b)(2.3b)(986.0m)
USDY, 2020

EV/CFO

304.9 x

Financial Leverage

3.2 x
Show all financial metrics

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018Apr, 2020

Drugs Approved by FDA

1

Phase III Trials Products

24 20 20 24

Products

30 98

Projects in R&D Pipeline

41 10
Show all operating metrics

Merck Acquisitions / Subsidiaries

Company NameDateDeal Size
Themis BioscienceMay 26, 2020
ArQuleDecember 09, 2019$2.70 b
Tilos TherapeuticsJune 10, 2019$773 m
Peloton TherapeuticsMay 21, 2019$2.25 b
Antelliq GroupDecember 14, 2018$2.40 b
ViralyticsFebruary 21, 2018$502 m
StayWellJuly 11, 2016
Afferent PharmaceuticalsJune 09, 2016$1.25 b
IOmet PharmaJanuary 13, 2016
cCAM BiotherapeuticsJuly 28, 2015$95 m
Show more

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 9.4% from Animal Health, 89.1% from Pharmaceutical and 1.5% from Other

Merck revenue breakdown by geographic segment: 6.3% from Asia Pacific (other than Japan and China), 6.8% from China, 5.3% from Latin America, 27.1% from Europe, Middle East and Africa, 43.4% from United States, 7.6% from Japan and 3.4% from Other

Merck Online and Social Media Presence

Embed Graph

Merck Company Culture

  • Overall Culture

    B+

    72/100

  • CEO Rating

    A

    75/100

  • Compensation

    A-

    75/100

  • Diversity

    A-

    76/100

Learn more on Comparably

Merck News and Updates

A Fundação Merck anuncia os prémios de jornalismo 'Fique em Casa' para países latino-americanos

SAN JOSÉ, Costa Rica, 21 de maio de 2020 /PRNewswire/ -- A Fundação Merck (www.merck-foundation.com), o braço filantrópico da Merck KGaA Germany anuncia o convite à apresentação de ccandidaturas para o prémios de jornalismo 'Fique em casa' para jornalistas dos países latino-americanos. O...

Merck Manuals Survey: 8 in 10 Medical Students Say COVID-19 and Remote Learning Have Impacted Their Study Habits

KENILWORTH, N.J., May 20, 2020 /PRNewswire/ -- The ongoing COVID-19 pandemic is having a significant impact on medical students. As universities have shifted to virtual learning models and online classes, students have had to shift their learning and study habits. To better understand...

Dow off 50 points at midday; P&G, Merck, Exxon, Chevron, Home Depot pace retreat

Dow off 50 points at midday; P&G, Merck, Exxon, Chevron, Home Depot pace retreat

3M, Merck and Pfizer sole components in black as Dow plummets 820 points

3M, Merck and Pfizer sole components in black as Dow plummets 820 points

Merck Will No Longer Be ‘Easy to Own’ on Keytruda Dominance

Merck Will No Longer Be ‘Easy to Own’ on Keytruda Dominance
Show more

Merck Blogs

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer

Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced the Risk of Disease Progression or Death by 35% Compared to Chemotherapy Alone as First-Li…

Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma

Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and Diverse Oncology Pipeline KENILWORTH, N.J.--(BUSINESS WIRE)--M…

Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals

Dateline City: MADISON, N.J. Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal Category with Comprehensive, Continuous Parasite Protection Complements Merck Animal H…

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab Alone (17.7 months) Following Response to Platinum-Based Chemotherapy with Bevacizumab…

KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas

Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), kn…

Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type

Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients Whose Tumors Are Tumor Mutational Burden-High (TMB-H) Who Have Progr…
Show more

Merck Frequently Asked Questions

  • When was Merck founded?

    Merck was founded in 1891.

  • Who are Merck key executives?

    Merck's key executives are Kenneth Frazier, Jim Scholefield and Robert Davis.

  • How many employees does Merck have?

    Merck has 71,000 employees.

  • What is Merck revenue?

    Latest Merck annual revenue is $46.8 b.

  • What is Merck revenue per employee?

    Latest Merck revenue per employee is $659.7 k.

  • Who are Merck competitors?

    Competitors of Merck include GlaxoSmithKline, Eli Lilly and Johnson & Johnson.

  • Where is Merck headquarters?

    Merck headquarters is located at 2000 Galloping Hill Rd, Kenilworth.

  • Where are Merck offices?

    Merck has offices in Kenilworth, Albany, Albuquerque, Alexandria and in 273 other locations.

  • How many offices does Merck have?

    Merck has 278 offices.